The OpenVal™ Future Forum brought together OpenVal™ customers to explore the future of the product and open-source in industry.  If you weren’t there, here’s a quick recap of the highlights you missed: 

Key Developments and Future Directions 

Ashley Tarasiewicz kicked off the discussion by reflecting on the progress of OpenVal™. Key themes included: 

  • Evolution of OpenVal™: Launched in January 2023, OpenVal™ is a subscription based validated package delivery system in support of the R programming language. It enables companies to transition smoothly from SAS to R, with a focus on traceability, reproducibility, and collaboration within industry. 
  • New Packages: This year, 92 packages were added to OpenVal™, including several key pharmaverse packages that support end-to-end clinical programming. 
  • Change Management: Throughout the year, 355 packages received version updates and improvements to testing processes. 
  • Communication and Transparency: To enhance client communication, detailed Release Notes, a Release Calendar, and Package Lists are now available on the Atorus website. 
  • Future Enhancements: Upcoming features will expand OpenVal™’s offerings, including user and administrative guides, sample environments and code, as well as code review tools. 

Real-World Applications 

Presentations from Johnson & Johnson and Formation Bio highlighted practical uses of OpenVal™: 

  • Johnson & Johnson: Nick Masel and Satish Murthy demonstrated how Johnson & Johnson effectively utilizes OpenVal™ in their work and shared their future plans for the product. 
  • Formation Bio: Melanie Hullings and Emily Yates discussed their experience adopting OpenVal™ to improve clinical trial execution and data management, as well as their processes for developing company guidelines on package validation. 

Industry Trends and Insights 

Mike Stackhouse discussed evolving industry trends, emphasizing the need for efficient build processes and the role of open-source collaboration in enhancing clinical programming: 

  • Open-Source Integration: OpenVal™ seeks to facilitate seamless integration, fostering collaboration among programmers. 
  • AI Exploration: The potential integration of AI tools could further enhance programming capabilities. 

Community Feedback and Future Roadmap 

An engaging discussion highlighted customer input on OpenVal™ version management, package validation processes, and regulatory perspectives on open-source software in clinical trials.  

The future of clinical programming is evolving rapidly, and being informed is key to leveraging these advancements effectively. Contact Atorus to learn how OpenVal™ can streamline your adoption of open-source solutions, and secure your spot in the next gathering of OpenVal™ customers. 

Back to Blog